364 related articles for article (PubMed ID: 24758333)
1. Impact of amino acid substitutions in the V2 and C2 regions of human immunodeficiency virus type 1 CRF01_AE envelope glycoprotein gp120 on viral neutralization susceptibility to broadly neutralizing antibodies specific for the CD4 binding site.
Utachee P; Isarangkura-na-ayuthaya P; Tokunaga K; Ikuta K; Takeda N; Kameoka M
Retrovirology; 2014 Apr; 11():32. PubMed ID: 24758333
[TBL] [Abstract][Full Text] [Related]
2. Two N-linked glycosylation sites in the V2 and C2 regions of human immunodeficiency virus type 1 CRF01_AE envelope glycoprotein gp120 regulate viral neutralization susceptibility to the human monoclonal antibody specific for the CD4 binding domain.
Utachee P; Nakamura S; Isarangkura-Na-Ayuthaya P; Tokunaga K; Sawanpanyalert P; Ikuta K; Auwanit W; Kameoka M
J Virol; 2010 May; 84(9):4311-20. PubMed ID: 20164234
[TBL] [Abstract][Full Text] [Related]
3. A 2-4-Amino Acid Deletion in the V5 Region of HIV-1 Env gp120 Confers Viral Resistance to the Broadly Neutralizing Human Monoclonal Antibody, VRC01.
Tachibana S; Sasaki M; Tanaka T; Inoue M; Ophinni Y; Kotaki T; Kameoka M
AIDS Res Hum Retroviruses; 2017 Dec; 33(12):1248-1257. PubMed ID: 28903577
[TBL] [Abstract][Full Text] [Related]
4. Three amino acid residues in the envelope of human immunodeficiency virus type 1 CRF07_BC regulate viral neutralization susceptibility to the human monoclonal neutralizing antibody IgG1b12.
Nie J; Zhao J; Chen Q; Huang W; Wang Y
Virol Sin; 2014 Oct; 29(5):299-307. PubMed ID: 25273335
[TBL] [Abstract][Full Text] [Related]
5. Selection pressure on HIV-1 envelope by broadly neutralizing antibodies to the conserved CD4-binding site.
Wu X; Wang C; O'Dell S; Li Y; Keele BF; Yang Z; Imamichi H; Doria-Rose N; Hoxie JA; Connors M; Shaw GM; Wyatt RT; Mascola JR
J Virol; 2012 May; 86(10):5844-56. PubMed ID: 22419808
[TBL] [Abstract][Full Text] [Related]
6. Hyperglycosylated stable core immunogens designed to present the CD4 binding site are preferentially recognized by broadly neutralizing antibodies.
Ingale J; Tran K; Kong L; Dey B; McKee K; Schief W; Kwong PD; Mascola JR; Wyatt RT
J Virol; 2014 Dec; 88(24):14002-16. PubMed ID: 25253346
[TBL] [Abstract][Full Text] [Related]
7. Phenotypic studies on recombinant human immunodeficiency virus type 1 (HIV-1) containing CRF01_AE env gene derived from HIV-1-infected patient, residing in central Thailand.
Utachee P; Jinnopat P; Isarangkura-Na-Ayuthaya P; de Silva UC; Nakamura S; Siripanyaphinyo U; Wichukchinda N; Tokunaga K; Yasunaga T; Sawanpanyalert P; Ikuta K; Auwanit W; Kameoka M
Microbes Infect; 2009 Mar; 11(3):334-43. PubMed ID: 19136072
[TBL] [Abstract][Full Text] [Related]
8. Identification of Novel Structural Determinants in MW965 Env That Regulate the Neutralization Phenotype and Conformational Masking Potential of Primary HIV-1 Isolates.
Qualls ZM; Choudhary A; Honnen W; Prattipati R; Robinson JE; Pinter A
J Virol; 2018 Mar; 92(5):. PubMed ID: 29237828
[TBL] [Abstract][Full Text] [Related]
9. Glycans flanking the hypervariable connecting peptide between the A and B strands of the V1/V2 domain of HIV-1 gp120 confer resistance to antibodies that neutralize CRF01_AE viruses.
O'Rourke SM; Sutthent R; Phung P; Mesa KA; Frigon NL; To B; Horthongkham N; Limoli K; Wrin T; Berman PW
PLoS One; 2015; 10(3):e0119608. PubMed ID: 25793890
[TBL] [Abstract][Full Text] [Related]
10. Mechanism of neutralization by the broadly neutralizing HIV-1 monoclonal antibody VRC01.
Li Y; O'Dell S; Walker LM; Wu X; Guenaga J; Feng Y; Schmidt SD; McKee K; Louder MK; Ledgerwood JE; Graham BS; Haynes BF; Burton DR; Wyatt RT; Mascola JR
J Virol; 2011 Sep; 85(17):8954-67. PubMed ID: 21715490
[TBL] [Abstract][Full Text] [Related]
11. Conserved Role of an N-Linked Glycan on the Surface Antigen of Human Immunodeficiency Virus Type 1 Modulating Virus Sensitivity to Broadly Neutralizing Antibodies against the Receptor and Coreceptor Binding Sites.
Townsley S; Li Y; Kozyrev Y; Cleveland B; Hu SL
J Virol; 2016 Jan; 90(2):829-41. PubMed ID: 26512079
[TBL] [Abstract][Full Text] [Related]
12. The role of conventional antibodies targeting the CD4 binding site and CD4-induced epitopes in the control of HIV-1 CRF01_AE viruses.
Thida W; Kuwata T; Maeda Y; Yamashiro T; Tran GV; Nguyen KV; Takiguchi M; Gatanaga H; Tanaka K; Matsushita S
Biochem Biophys Res Commun; 2019 Jan; 508(1):46-51. PubMed ID: 30470571
[TBL] [Abstract][Full Text] [Related]
13. Molecular evolution of HIV-1 CRF01_AE Env in Thai patients.
Boonchawalit S; Jullaksorn D; Uttiyoung J; Yowang A; Krathong N; Chautrakul S; Yamashita A; Ikuta K; Roobsoong A; Kanitvittaya S; Sawanpanyalert P; Kameoka M
PLoS One; 2011; 6(11):e27098. PubMed ID: 22073263
[TBL] [Abstract][Full Text] [Related]
14. CD4-Induced Antibodies Promote Association of the HIV-1 Envelope Glycoprotein with CD4-Binding Site Antibodies.
Gardner MR; Fellinger CH; Prasad NR; Zhou AS; Kondur HR; Joshi VR; Quinlan BD; Farzan M
J Virol; 2016 Sep; 90(17):7822-32. PubMed ID: 27334589
[TBL] [Abstract][Full Text] [Related]
15. Biochemically defined HIV-1 envelope glycoprotein variant immunogens display differential binding and neutralizing specificities to the CD4-binding site.
Feng Y; McKee K; Tran K; O'Dell S; Schmidt SD; Phogat A; Forsell MN; Karlsson Hedestam GB; Mascola JR; Wyatt RT
J Biol Chem; 2012 Feb; 287(8):5673-86. PubMed ID: 22167180
[TBL] [Abstract][Full Text] [Related]
16. Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1.
Roben P; Moore JP; Thali M; Sodroski J; Barbas CF; Burton DR
J Virol; 1994 Aug; 68(8):4821-8. PubMed ID: 7518527
[TBL] [Abstract][Full Text] [Related]
17. HIV-1 envelope glycan modifications that permit neutralization by germline-reverted VRC01-class broadly neutralizing antibodies.
LaBranche CC; McGuire AT; Gray MD; Behrens S; Kwong PDK; Chen X; Zhou T; Sattentau QJ; Peacock J; Eaton A; Greene K; Gao H; Tang H; Perez LG; Chen X; Saunders KO; Kwong PD; Mascola JR; Haynes BF; Stamatatos L; Montefiori DC
PLoS Pathog; 2018 Nov; 14(11):e1007431. PubMed ID: 30395637
[TBL] [Abstract][Full Text] [Related]
18. HIV gp120 H375 is unique to HIV-1 subtype CRF01_AE and confers strong resistance to the entry inhibitor BMS-599793, a candidate microbicide drug.
Schader SM; Colby-Germinario SP; Quashie PK; Oliveira M; Ibanescu RI; Moisi D; Mespléde T; Wainberg MA
Antimicrob Agents Chemother; 2012 Aug; 56(8):4257-67. PubMed ID: 22615295
[TBL] [Abstract][Full Text] [Related]
19. Naturally occurring substitutions of conserved residues in human immunodeficiency virus type 1 variants of different clades are involved in PG9 and PG16 resistance to neutralization.
Thenin S; Roch E; Samleerat T; Moreau T; Chaillon A; Moreau A; Barin F; Braibant M
J Gen Virol; 2012 Jul; 93(Pt 7):1495-1505. PubMed ID: 22492917
[TBL] [Abstract][Full Text] [Related]
20. Characterization of human immunodeficiency virus type 1 CRF01_AE env genes derived from recently infected Thai individuals.
Chaitaveep N; Utachee P; Nakamura S; Chuenchitra T; Ekpo P; Takeda N; Pattanapanyasat K; Kameoka M
Microbes Infect; 2014 Feb; 16(2):142-52. PubMed ID: 24513704
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
